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Human parvovirus B19 (B19) infects human erythroid lineage cells. Accumulating evidence also shows that B19 is detectable in nonerythroid
lineage cells in vivo, but the mechanism of infection is still not clear. In this study, we explored the mode of B19 infection of human monocytic
cell line U937. An in vitro infection study demonstrated B19 binding of U937 and slow replication of B19-DNA with B19-NS1 mRNA
transcription. B19-DNA replication in U937 was accompanied by undetectable level of B19-VP1 mRNA transcription, indicating that B19
infection of U937 cells may be abortive. Levels of B19-DNA and B19-NS1 mRNA transcription increased in the presence of anti-B19 IgG
antibodies, but this effect decreased in the presence of anti-Fc receptor antibodies, showing antibody-dependent enhancement by B19 infection.
Antibody-dependent enhancement also caused the increased production of TNFa in U937. This study is the first to suggest B19 infection of
nonerythroid lineage cells with antibody-dependent enhancement.
D 2005 Elsevier Inc. All rights reserved.Keywords: Parvovirus B19; Antibody-dependent enhancement; TNFaIntroduction
Human parvovirus B19 (B19) is an erythrovirus that
infects human erythroid lineage cells and causes hemolytic
anemia or hydrops fetalis (Brown and Young, 1997). The
B19 genome includes major open reading frames coding for
nonstructural protein NS1 and structural proteins VP1 and
VP2 (Shade et al., 1986). The cellular receptor for B19
infection has been identified as P antigen that is a glycolipid
expressed on erythroid lineage cells (Brown et al., 1993).
However, B19 is often detectable in nonerythroid cells in
vivo (Anderson et al., 1985; Isumi et al., 1999; Ray et al.,
2001; Takahashi et al., 1998; Weigel-Kelley et al., 2001).
B19 infection may also cause autoantibody production, such
as rheumatoid factors, anti-nuclear antibody, anti-DNA
antibody or anti-phospholipid antibody and autoimmune
disease-like signs (Kerr, 2000; Lehmann et al., 2003; Ochiai0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.09.040
* Corresponding author. Fax: +81 22 717 7168.
E-mail address: mnkt@mail.tains.tohoku.ac.jp (Y. Munakata).et al., 1988). We have recently described the presence of
B19-DNA, mRNA and protein (VP1) in macrophages,
follicular dendritic cells, T cells and B cells in synovial
tissues from patients with rheumatoid arthritis. VP1 has been
detected in U937 monocytic cell line when coincubated with
rheumatoid synovial cells in vitro (Takahashi et al., 1998).
These findings are unexplainable solely by B19 infection of
erythroid cells. Hemophagocytic syndrome or necrotizing
lymphadenitis, where proinflammatory cytokines such as
tumor necrosis factor alpha (TNFa) from phagocytes are
responsible for the pathogenesis, is accompanied by B19
infection (Johnson et al., 2003; Larroche et al., 2002; Lay et
al., 1997), and we have shown that transfection of the B19-
NS1 gene into U937 leads to an increased production of
TNFa (Fu et al., 2002). Verification of B19 infection in
nonerythroid cells, especially those that function as phago-
cytes, may provide crucial information on clinical problems
of B19 infection.
In this study, we investigated the mode of B19 infection of
nonerythroid cells by assessing in vitro B19 infection of U937
monocytic cell line that is supposed to be the experimental6) 251 – 257
www.e
Fig. 1. B19 infection of U937 cell line. (A) B19-DNA replication in U937 cells
detected by PCR. U937 cells were incubated with B19 for 0, 2, 4, 8 and 12
days. DNA was extracted at each time point, and B19-DNA was measured by
PCR in triplicate. The average copy number of B19-DNA in total cell culture
and standard deviation was shown. (B) Detection of B19-mRNA in U937 cells
by RT-PCR. U937 cells were incubated with B19 for 6 days. RNA was
extracted, and B19-RNA was measured by RT-PCR in triplicate. The average
copy number of B19-DNA in proportion to 1010 copies of GAPDH mRNA and
standard deviation are shown. RT-PCR was done by using sets of primers fo
NS1 and VP1 (RT(+)), and, at the same time, PCR was also done withou
reverse transcription to evaluate contamination of DNA (RT()).
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(APC) and also explored whether antibody-dependent en-
hancement (ADE) may be involved in B19 infection of U937
because anti-viral neutralizing antibodies which bind to the Fc
receptor on phagocytes often facilitate viral infection of their
target cells, resulting in persistent infection in vivo (Cancel
Tirado and Yoon, 2003; Halstead, 1988; Halstead and
O’Rourke, 1977; Hawkes, 1964).
Results
B19-DNA was detected in PBMC from patients with acute B19
infection
To explore the possibility of B19 infection of nonerythroid
lineage cells in vivo, we first examined the presence of B19-
DNA in PBMC in patients with acute B19 infection. B19-DNA
was detected at 15,864 T 1592 copies/Ag DNA in isolated
PBMC and at 3492 T 122 copies/Ag DNA even after the
treatment with pronase. Nuclear extract from the same PBMC
contained 2926 T 204 copies/Ag DNA of B19-DNA. The
difference between the B19-DNA copy number in pronase-
treated PBMC and in the nuclear extract showed no statistical
significance. Copy numbers of B19-DNA from uninfected
normal subjects were below 10 copies. Copy numbers of
B19-DNA in PBMC from normal subjects were below 200
copies at 10 min after B19 inoculation in vitro (data not
shown).
B19 shows abortive infection in U937 monocytic cell line
To know if nonerythroid cells participate in B19 infection in
vitro, we examined the replication of B19-DNA in U937
monocytic cell line as the model of B19 infection to
nonerythroid cells. P antigen, the known B19 receptor, was
not detectable on the surface of U937 (data not shown). Initial
adsorption of B19 to U937 was observed at Day 0 (43,300 T
2600 copies). The copy number of B19-DNA decreased to
7100 T 600 copies at Day 4 (Fig. 1A), and it tended to increase
from Day 4. The copy number of B19-DNA at Day 12 was
14,500 T 1700, which was a statistically significant increase
compared with the copy number at Day 4 (P < 0.01). Next, we
evaluated the transcription of B19-mRNA in U937 cells. We
detected 2031 T 164 copies/(1010 copies of GAPDH mRNA) of
B19-NS1 mRNA at Day 6 by using quantitative RT-PCR but
was not detected without reverse transcription (Fig. 1B).
However, B19-VP1 mRNA was not detectable by the
quantitative RT-PCR assay.
Antibody-dependent enhancement of B19 infection in U937
cells
To investigate the effect of IgG anti-B19 antibody at B19
infection, we added purified human IgG to the in vitro B19
infection system of U937 cells. We detected neither IgM nor
IgG anti-B19 antibody activity in ET, where anti-B19
neutralizing activity was negative. But, IgG from MT, YMr
tand TS healthy volunteers had anti-B19 antibody activity and
markedly inhibited B19 proliferation, when added to KU812Ep6
cells at B19 infection. This is not the case at B19 infection of
U937 cells. The incubation of U937 cells caused an enhanced
increase of B19-DNA in the presence of purified human IgG
from MT, YM and TS (Fig. 2A). The maximum effect of the
increase on B19-DNA replication by IgG anti-B19 antibody
occurred at concentration 10 Ag/ml in IgG samples from MT,
YM and TS. The maximum copy number of B19-DNA
(1,930,000 T 192,000 copies) with IgG from MT at this time
increased more than 83 times, compared with the copy number
of B19-DNA (23,000 T 10,400 copies) without IgG (Fig. 3A).
In case of IgG from YM or TS, the maximum copy number of
B19-DNA (670,000 T 163,000 and 546,000 T 253,000 copies,
respectively) increased more than 246 or 107 times, compared
with the copy number of B19-DNA (2720 T 197 and 5100 T 232
copies, respectively) without IgG, respectively (Fig. 3A). An
increased association of B19 to U937 cells in the presence of
IgG anti-B19 antibody was seen from Day 0 in MT, YM and
TS when compared with that in ET, which had no
neutralizing activity against B19. Increased B19-DNA repli-
cation tended to be seen after Day 4 for MT, YM and TS, and
the effect of the increase on B19-DNA replication continued
Fig. 3. Inhibition of ADE by anti-Fc antibodies. In vitro B19 infection of U937
was done in the presence or absence of 10 Ag/ml of IgG anti-B19 antibodies
from ET or MT. At the same time, anti-Fc antibodies or isotype-matched
control antibody 1F5 were added to the culture as the competitor for ADE at 0,
1 and 5 Ag/ml concentrations. DNA was extracted at Day 8. B19-DNA was
measured by PCR in triplicate. The average copy number of B19-DNA in total
cell culture and standard deviation are shown.
Fig. 4. Secretion of TNFa in culture supernatant of U937 infected with B19.
In vitro B19 infection of U937 was done in the presence of 10 Ag/ml of IgG
anti-B19 antibodies from MT (n) or ET (g). The concentration of TNFa
secreted in the culture supernatant was measured by ELISA in triplicate on 0,
4 and 9 days. The average amount of TNFa in total cell culture and standard
deviation are shown.
Fig. 2. B19 infection of U937 cell line in the presence of IgG anti-B19
antibodies. (A) B19-DNA detected in U937 cells in the presence of IgG anti-
B19 antibodies at Day 8 of incubation. In vitro B19 infection of U937 was done
in the presence of various concentrations of IgG anti-B19 antibodies from MT
(.), YM (n) and TS (o) as indicated. B19-DNA was measured by PCR in
triplicate. The average copy number of B19-DNA in total cell culture and
standard deviation were shown. (B) B19-DNA detected in U937 cells in the
presence of 10 Ag/ml of IgG anti-B19 antibodies. In vitro B19 infection of
U937 was done in the presence of IgG anti-B19 antibodies from MT (.), YM
(n), TS (o) and ET (q) for 0, 4, 8, 12 and 20 days. DNAwas extracted at each
time point. B19-DNA was measured by PCR in triplicate. The average copy
number of B19-DNA in total cell culture and standard deviation are shown.
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increase of B19-DNA induced by the presence of IgG anti-
B19 antibody was inhibited by adding anti-Fc receptor
antibodies. Increased B19-DNA by 10 Ag/ml of IgG from
MT at Day 8 was significantly inhibited by the presence of 5
Ag/ml of anti-Fc receptor antibody, but the increased B19-
DNA replication was not reduced in the presence of the same
concentration of the control antibody 1F5 (Fig. 3).
Increased production of TNFa
We measured the amount of TNFa produced in the culture
media of the in vitro B19 infection system of U937 by usingELISA. The level of TNFa production significantly increased
in the presence of IgG from MT that had reactivity against B19,
but not in the presence of IgG from ET that had no reactivity
against B19 (Fig. 4).
ADE was also observed in bone marrow samples
The increase of B19-DNA induced by the presence of IgG
anti-B19 antibody was also observed in bone marrow samples,
and increased B19-DNA was significantly inhibited by adding
anti-Fc receptor antibodies like in case of U937 (Fig. 5A).
Fig. 5. ADE in B19 infection of bone marrow cells. (A) Enhanced B19-DNA
replication in the presence of anti-B19 antibody and its inhibition by anti-Fc
antibodies in B19 infection of bone marrow cells. In vitro B19 infection of bone
marrow cells was done in the presence or absence of 10 Ag/ml of IgG anti-B19
antibodies from MT. At the same time, anti-Fc antibodies were added to the
culture as the competitor for ADE at 0 and 5 Ag/ml concentrations. DNA was
extracted at Day 5. B19-DNAwas measured by PCR in triplicate. The average
copy number of B19-DNA in total cell culture and standard deviation are
shown. *P < 0.01. (B) Enhanced TNFa secretion in culture supernatant of bone
marrow cells infected with B19. In vitro B19 infection of bone marrow cells
was done in the presence of 10 Ag/ml of IgG anti-B19 antibodies from MT. The
concentration of TNFa secreted in the culture supernatant was measured by
ELISA in triplicate on 0 and 5 days. The average amount of TNFa in total cell
culture and standard deviation are shown. *P < 0.05.
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significantly in the presence of IgG from MT (Fig. 5B).
Discussion
The participation of nonerythroid cells in B19 infection in
vitro has not so far been described. This is attributed to the
evidence that only erythroid cells expressing P antigen are
permissive to B19 infection that produces the B19 protein
VP1. We here demonstrated that B19 infection was involved
in nonerythroid cells, especially immune cells, because: B19-
DNA was detectable in the nuclear fraction of PBMC from
patients with acute B19 infection (Anderson et al., 1985);
monocytic cell line U937 bound B19 in vitro (Brown and
Young, 1997); B19-DNA replication in U937 was slow, but
the B19-DNA levels increased at Day 12 when comparedwith at Day 4 of B19 inoculation (Brown et al., 1993); ADE
occurs at B19 infection of Fc receptor-positive cells (Cancel
Tirado and Yoon, 2003).
Despite the marked association of B19 to U937 at Day 0,
B19-DNA decreased at Day 4. Then, B19-DNA gradually
increased after that. This indicated that the limited numbers of
B19 entered into the cells. B19 infection of U937 cells,
however, may be abortive because the infection is not
accompanied by the production of viral particle. One mecha-
nism that may explain the reason why B19 infection fails to
cause capsid protein synthesis in U937 is that nonerythroid
cells may lack cellular factors needed for B19 replication (Ray
et al., 2001; Rhode and Paradiso, 1989), although we have no
evidence at present. The defective translocation of NS1 protein
into the nucleus may also be responsible for this mechanism as
shown at fibroblasts in the case of parvovirus H-1 (H-1) in the
Parvoviridae (Rhode and Paradiso, 1989). Another possibility
is the effect of TNFa which is produced in B19-infected U937
(Fu et al., 2002), and this may cause an incomplete shut-off of
host protein synthesis, resulting in the inefficient replication of
the virus (Lopez-Guerrero et al., 1990). The production of
nitric oxide and superoxide anions may also indicate abortive
H-1 infection in U937 (Lopez-Guerrero et al., 1997). Thus,
B19 infection failed to cause the production of B19 particle in
monocytic cell line U937. However, we cannot conclude that
B19 infection of macrophages is abortive in vivo because B19-
VP1 and VP1 mRNA were positive in macrophages or T cells
at acute B19 infection or in rheumatoid synovium (Takahashi et
al., 1998). It should be here noted that, although influenza virus
infection of lymphocytes is abortive in vitro, the lymphocytes
can synthesize influenza virus proteins when infected with the
virus in the presence of macrophages (Mock et al., 1987).
The ADE mechanism was first described for flaviviruses
(Hawkes, 1964) and then for a number of other viruses,
including influenza virus (Ochiai et al., 1988), dengue virus
(Halstead and O’Rourke, 1977), HIV-1 (Robinson et al., 1988;
Takeda et al., 1988), rabies virus (Porterfield, 1981) and the
parvoviridae Aleutian mink disease parvovirus (Kanno et al.,
1993). The mechanism by which ADE of virus infection is
mediated is primarily through interaction of the Fc region of
virus-specific IgG and Fc receptors on the surface of phagocytes
(Peiris et al., 1981). IgG anti-B19 antibody from healthy
volunteers also had a strong inhibitory ability for B19 infection
in erythroid cell line KU812Ep6 that lacked Fc receptor on their
surface (data not shown) but enhanced B19-DNA replication in
macrophage cell line U937 when added at the initial phase of
B19 infection. We believe that this study is the first one to show
ADE in human parvovirus B19 infection. Like other types of
virus infection, ADE in B19 infection was mediated by the Fc
receptor on the cell surface. Of importance is that ADE may also
occur in vivo and may associate with the life-threatening
dengue hemorrhagic fever and dengue shock syndrome
(Halstead, 1988). Many studies also have indicated the role of
ADE in persistent infection of viruses (Cancel Tirado and Yoon,
2003). It is actually plausible to speculate that ADE in B19
infection occurs in vivo since the infection to the bone marrow
cells of B19 is enhanced in the presence of IgG anti-B19
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production of TNFa was also enhanced, although quantity of
production was lower than that observed in U937. This may be
due to the heterogeneity of bone marrow cells. As the bone
marrow cells consist of variety lineage cells, B19 may infect to
cells that have no capability of TNFa production.
It is worth to discuss here the presented data in association
with a variety of clinical observation that are difficult to explain
solely by the mechanism for the apoptosis induction in B19-
infected erythroid lineage cells at acute B19 infection (Moffatt
et al., 1998; Ozawa et al., 1988). One of the clinical features of
B19 infection is prolonged or persistent infection where
autoantibody production, autoimmune disease-like signs or
the production of inflammatory cytokines such as TNFa and
interferon-gamma is often accompanied, indicating the role of
immune system at B19 infection. This paper demonstrates the
role of B19 infection in immune abnormality in macrophage
cell line U937, where TNFa is markedly secreted at ADE
mechanism. It is, therefore, reasonable to speculate that
infection of B19 in immune cells may associate with a variety
of immune abnormalities that associate with pathogenesis of
rheumatoid arthritis (Takahashi et al., 1998).
Materials and methods
Cells
Human monocytic cell line U937 was provided by the Cell
Resource Center for Biomedical Research, Institute of Devel-
opment, Aging and Cancer, Tohoku University. Human
erythroid cell line KU812Ep6 was kindly provided by E.
Miyagawa at the Institute of Fuji Rebio Inc (Tokyo, Japan)
(Miyagawa et al., 1999). The U937 cell lines were cultured in
RPMI medium supplemented with 10% fetal bovine serum
(FBS) and 50 Ag (each) of streptomycin and penicillin (Gibco
BRL, Carlsbad, CA) per milliliter in a 5% CO2 atmosphere at
37 -C. KU812Ep6 cells were cultured with the same medium
containing 6 IU/ml of erythropoietin (Kirin Brewery Inc.,
Tokyo, Japan). Bone marrow samples were obtained from the
volunteers who gave informed consent for the use of their
samples for our study.
Human parvovirus B19
Serum from patient FU with acute B19 infection was used
for in vitro infection assay. The serum contained 2.5  1014
copies of B19-DNA per milliliter, and anti-B19 antibodies
were not detected by using enzyme-linked immunosorbent
assay (ELISA).
Human IgG samples
Human IgG was purified from serum of each normal
volunteer (MO, ET, MT, YM and TS) by using MAbTrapG2
(Amersham Pharmacia Biotech, Piscataway, NJ). The titers of
anti-B19 IgM and anti-B19 IgG were measured by using a
commercial indirect ELISA kit (Denka Seiken Inc., Tokyo,Japan). The titer of anti-B19 antibodies in the original serum
was expressed as an index according to the instructions
provided, and an index number over 0.8 was positive for the
presence of anti-B19 antibodies. The titers of anti-B19 IgM
were below 0.8 in all samples tested. The titers of anti-B19 IgG
in MO, ET, MT, YM and TS were <0.8, <0.8, 10.2, 9.8 and
9.5, respectively. The neutralizing activity for B19 infection in
the original serum was measured as described previously (Saito
et al., 2003). There is no neutralizing activity in MO and ET.
The neutralizing activity of MT, YM and TS was 93%, 60%
and 55%, respectively.
Pronase treatment of PBMC
Peripheral blood mononuclear cells (PBMC) were obtained
from patients with acute B19 infection by density gradient
centrifugation on Ficoll-Paque (Amersham Biosciences,
Uppsala, Sweden). Cells were suspended in PBS at concentra-
tion 5  106/ml, and 0.25 mg/ml of pronase was added. Cells
were incubated at 37 -C for 60 min, and then an equal volume
of pre-chilled 10% FBS-RPMI was added to stop the pronase
reaction. The cells were washed with PBS three times, and then
they were underwent DNA extraction.
DNA and RNA extraction
DNA was prepared from cells by using a conventional
phenol-chloroform method. RNA was extracted from cells by
using the acid guanidium-phenol chloroform method and using
Isogen-LS (Nippon Gene, Toyama, Japan) twice. To remove
DNA, 1 unit/ml of DNase (Ambion, Austin, TX) was added to
the RNA suspension.
Quantitative PCR assay
A quantitative PCR assay of samples amplified the VP1-
region of B19-DNA as described previously (Saito et al.,
2003). The primers and probe used to detect VP1 were:
forward primer, 5V-CCCTAGAAAACCCATCCTCTGTG-3V;
reverse primer, 5V-AGGTTCTGCATGACTGCTACTGG-3V;
probe, 5V-TCATGGACAGTTATCTGACCACCCCCA-3V. A
quantitative PCR assay to detect the NS1 region of B19-
DNA was done by using the same procedure and replacing the
PCR primers and probe. The primers and probe used to detect
NS1 were: forward primer, 5V-AACCCCGCGCTCTAGTACG-
3V; reverse primer, 5V-CTGGGCTTCCGACAAATGA-3V;
probe, 5V-CATCCCCGGGACCAGTTCAGG-3V.
Quantitative RT-PCR assay
Total RNA samples (1 Ag) were subjected to quantitation of
B19-NS1 mRNA, B19-VP1 mRNA and human glyceralde-
hydes-3-phosphate dehydrogenese (GAPDH) mRNA. The
quantity of each mRNA was measured by using a method
based on the TaqMan protocol (Applied Biosystem, Foster
City, CA). Reverse transcription and PCR (RT-PCR) was done
in a one-step reaction as described previously (Fu et al., 2002).
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Human monocytic cell line U937 (4  106 cells/ml) was
mixed with human serum FU that contained 2.5  1014 copies
of B19-DNA/ml from a patient with acute B19 infection. The
final concentration of the B19 serum FU was 1:2500. For the
experiment of human IgG MT addition, B19 serum FU was
appropriately diluted with 10% FBS-RPMI medium containing
human IgG MT and was incubated at 37 -C for 1 h before the
cell culture. The cells were incubated at 37 -C in 5% CO2 for
12 h. The cells were washed three times with PBS and were
adjusted to 5  105 cells/ml and were further cultured with
10% FBS-RPMI medium at 37 -C in 5% CO2. For the blocking
experiment of Fc receptor, U937 cells were incubated for 1
h with 0.5 Ag/ml or 2.5 Ag/ml of anti-CD32 and anti-CD64
monoclonal antibodies (PharMingen, San Diego, CA) at 4 -C,
were washed three times with PBS and then were used for the
B19 infection experiment described above.
Human bone marrow cells (1  105/ml) were incubated with
B19 serum FU in the presence or absence of human IgG MT at
same manner described above and cultured with 10% FBS-
RPMI medium at 37 -C in 5% CO2 for 5 days. Then, they were
subjected for DNA extraction to evaluate quantity of B19-DNA
by PCR. Culture supernatant was collected at Day 5 and
measured the concentration of TNFa.
ELISA for measuring TNFa
The amount of human TNFa in the culture supernatant was
measured by using an ultrasensitive ELISA kit (BioSource
International, Camarillo, CA) in triplicate. The minimum
detectable dose of TNFa was <0.09 pg/ml, according to the
manufacturer’s instructions.
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